$NOVN Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in NOVEN PHARMACEUTICALS INC.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in NOVEN PHARMACEUTICALS INC. Get notifications about new insider transactions in NOVEN PHARMACEUTICALS INC for free.
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Venditti Anthony | VP - Marketing and ... | Option Exercise | D | 11.09 | 39,037 | 432,920 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Venditti Anthony | VP - Marketing and ... | Option Exercise | D | 10.69 | 79,139 | 845,996 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Option Exercise | D | 11.09 | 66,921 | 742,154 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Option Exercise | D | 13.93 | 62,500 | 870,625 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Lippman Joel | VP and Chief Medica ... | Option Exercise | D | 11.09 | 33,460 | 371,071 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Lippman Joel | VP and Chief Medica ... | Option Exercise | D | 10.86 | 78,520 | 852,727 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | DINH STEVEN M | VP & Chief Scientif ... | Option Exercise | D | 11.09 | 39,037 | 432,920 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | DINH STEVEN M | VP & Chief Scientif ... | Option Exercise | D | 11.84 | 53,107 | 628,787 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Gilbert Richard P. | Vice President - Op ... | Option Exercise | D | 11.09 | 66,921 | 742,154 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Gilbert Richard P. | Vice President - Op ... | Option Exercise | D | 14.54 | 29,806 | 433,379 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Gilbert Richard P. | Vice President - Op ... | Option Exercise | D | 22.83 | 19,908 | 454,500 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Gilbert Richard P. | Vice President - Op ... | Option Exercise | D | 13.68 | 23,191 | 317,253 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Gilbert Richard P. | Vice President - Op ... | Option Exercise | D | 16.35 | 30,000 | 490,500 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Executive Vice Pres ... | Option Exercise | D | 11.09 | 71,701 | 795,164 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Executive Vice Pres ... | Option Exercise | D | 14.54 | 52,161 | 758,421 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Executive Vice Pres ... | Option Exercise | D | 22.83 | 23,527 | 537,121 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Executive Vice Pres ... | Option Exercise | D | 13.68 | 30,864 | 422,220 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Executive Vice Pres ... | Option Exercise | D | 22.60 | 50,000 | 1,130,000 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Executive Vice Pres ... | Option Exercise | D | 10.45 | 24,000 | 250,800 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Executive Vice Pres ... | Option Exercise | D | 13.11 | 19,099 | 250,388 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Executive Vice Pres ... | Sell | D | 16.50 | 1,835 | 30,278 | 0 | 1.8 K to 0 (-100.00 %) |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Yetter Wayne P. | Director | Option Exercise | D | 17.41 | 7,500 | 130,575 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Yetter Wayne P. | Director | Option Exercise | D | 18.73 | 7,500 | 140,475 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Yetter Wayne P. | Director | Option Exercise | D | 11.30 | 2,500 | 28,250 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Yetter Wayne P. | Director | Option Exercise | D | 9.74 | 5,000 | 48,700 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Yetter Wayne P. | Director | Option Exercise | D | 21.15 | 5,000 | 105,750 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Yetter Wayne P. | Director | Option Exercise | D | 19.66 | 12,500 | 245,750 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Yetter Wayne P. | Director | Sell | D | 16.50 | 11,309 | 186,599 | 0 | 11.3 K to 0 (-100.00 %) |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Option Exercise | D | 9.47 | 62,712 | 593,883 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Option Exercise | D | 11.09 | 188,471 | 2,090,143 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Option Exercise | D | 9.10 | 311,529 | 2,834,914 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Sell | U | 16.50 | 183,333 | 3,024,995 | 0 | 183.3 K to 0 (-100.00 %) |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Savage Robert G. | Director | Option Exercise | D | 17.41 | 7,500 | 130,575 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Savage Robert G. | Director | Option Exercise | D | 18.73 | 7,500 | 140,475 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Savage Robert G. | Director | Option Exercise | D | 18.90 | 15,000 | 283,500 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Savage Robert G. | Director | Sell | D | 16.50 | 9,120 | 150,480 | 0 | 9.1 K to 0 (-100.00 %) |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Nader Francois | Director | Sell | D | 16.50 | 10,943 | 180,560 | 0 | 10.9 K to 0 (-100.00 %) |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Option Exercise | D | 16.67 | 44,297 | 738,431 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Sell | D | 16.50 | 9,120 | 150,480 | 0 | 9.1 K to 0 (-100.00 %) |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Option Exercise | D | 17.41 | 7,500 | 130,575 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Option Exercise | D | 22.53 | 15,000 | 337,950 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Sell | D | 16.50 | 9,120 | 150,480 | 0 | 9.1 K to 0 (-100.00 %) |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Option Exercise | D | 17.41 | 7,500 | 130,575 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Option Exercise | D | 18.73 | 7,500 | 140,475 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Option Exercise | D | 18.90 | 15,000 | 283,500 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Sell | D | 16.50 | 9,120 | 150,480 | 0 | 9.1 K to 0 (-100.00 %) |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | CLARKSON JOHN G | Director | Option Exercise | D | 17.41 | 7,500 | 130,575 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | CLARKSON JOHN G | Director | Option Exercise | D | 18.73 | 7,500 | 140,475 | 0 | |
Aug 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | CLARKSON JOHN G | Director | Sell | D | 16.50 | 9,120 | 150,480 | 0 | 9.1 K to 0 (-100.00 %) |
Aug 21 2009 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Sell | U | 16.50 | 25,000 | 412,500 | 0 | 25 K to 0 (-100.00 %) |
Aug 21 2009 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Executive Vice Pres ... | Sell | U | 16.50 | 11,846 | 195,459 | 1,835 | 13.7 K to 1.8 K (-86.59 %) |
Aug 21 2009 | NOVN | NOVEN PHARMACEUTIC ... | Yetter Wayne P. | Director | Sell | U | 16.50 | 35,082 | 578,853 | 11,309 | 46.4 K to 11.3 K (-75.62 %) |
Aug 21 2009 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Sell | U | 16.50 | 111,667 | 1,842,506 | 183,333 | 295 K to 183.3 K (-37.85 %) |
Aug 21 2009 | NOVN | NOVEN PHARMACEUTIC ... | Savage Robert G. | Director | Sell | U | 16.50 | 23,659 | 390,374 | 9,120 | 32.8 K to 9.1 K (-72.18 %) |
Aug 21 2009 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Sell | U | 16.50 | 47,159 | 778,124 | 9,120 | 56.3 K to 9.1 K (-83.80 %) |
Aug 21 2009 | NOVN | NOVEN PHARMACEUTIC ... | Nader Francois | Director | Sell | U | 16.50 | 3,648 | 60,192 | 10,943 | 14.6 K to 10.9 K (-25.00 %) |
Aug 21 2009 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Sell | U | 16.50 | 32,817 | 541,481 | 9,120 | 41.9 K to 9.1 K (-78.25 %) |
Aug 21 2009 | NOVN | NOVEN PHARMACEUTIC ... | CLARKSON JOHN G | Director | Sell | U | 16.50 | 23,259 | 383,774 | 9,120 | 32.4 K to 9.1 K (-71.83 %) |
Aug 21 2009 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Sell | U | 16.50 | 33,659 | 555,374 | 9,120 | 42.8 K to 9.1 K (-78.68 %) |
May 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Savage Robert G. | Director | Grant | A | 0.00 | 12,160 | 0 | 32,779 | 20.6 K to 32.8 K (+58.97 %) |
May 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Grant | A | 0.00 | 12,160 | 0 | 56,279 | 44.1 K to 56.3 K (+27.56 %) |
May 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Grant | A | 0.00 | 12,160 | 0 | 41,937 | 29.8 K to 41.9 K (+40.84 %) |
May 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Grant | A | 0.00 | 12,160 | 0 | 42,779 | 30.6 K to 42.8 K (+39.71 %) |
May 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | CLARKSON JOHN G | Director | Grant | A | 0.00 | 12,160 | 0 | 32,707 | 20.5 K to 32.7 K (+59.18 %) |
May 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Yetter Wayne P. | Director | Grant | A | 0.00 | 15,078 | 0 | 46,391 | 31.3 K to 46.4 K (+48.15 %) |
May 27 2009 | NOVN | NOVEN PHARMACEUTIC ... | Nader Francois | Director | Grant | A | 0.00 | 14,591 | 0 | 14,591 | 0 to 14.6 K |
Mar 12 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 9.00 | 11,324 | 101,916 | 2,486,444 | 2.5 M to 2.5 M (-0.45 %) |
Mar 06 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 9.34 | 1,100 | 10,274 | 2,497,768 | 2.5 M to 2.5 M (-0.04 %) |
Mar 06 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 9.02 | 232,000 | 2,092,640 | 2,498,868 | 2.7 M to 2.5 M (-8.50 %) |
Mar 04 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 9.65 | 529 | 5,105 | 2,730,868 | 2.7 M to 2.7 M (-0.02 %) |
Feb 23 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 9.65 | 5,398 | 52,091 | 2,731,397 | 2.7 M to 2.7 M (-0.20 %) |
Feb 23 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 9.65 | 7,000 | 67,550 | 2,736,795 | 2.7 M to 2.7 M (-0.26 %) |
Feb 19 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 9.65 | 10,000 | 96,500 | 2,743,795 | 2.8 M to 2.7 M (-0.36 %) |
Feb 19 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 9.68 | 17,000 | 164,560 | 2,753,795 | 2.8 M to 2.8 M (-0.61 %) |
Feb 17 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 9.91 | 21,561 | 213,670 | 2,770,795 | 2.8 M to 2.8 M (-0.77 %) |
Feb 17 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 10.01 | 14,140 | 141,541 | 2,792,356 | 2.8 M to 2.8 M (-0.50 %) |
Feb 06 2009 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Option Exercise | A | 9.47 | 62,712 | 593,883 | 62,712 | |
Feb 02 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 9.98 | 25,000 | 249,500 | 2,806,496 | 2.8 M to 2.8 M (-0.88 %) |
Feb 02 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 10.10 | 25,000 | 252,500 | 2,831,496 | 2.9 M to 2.8 M (-0.88 %) |
Jan 21 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 11.00 | 100,000 | 1,100,000 | 2,956,496 | 3.1 M to 3 M (-3.27 %) |
Jan 29 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 10.55 | 50,000 | 527,500 | 2,856,496 | 2.9 M to 2.9 M (-1.72 %) |
Jan 29 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 10.32 | 50,000 | 516,000 | 2,906,496 | 3 M to 2.9 M (-1.69 %) |
Jan 13 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 11.00 | 7,989 | 87,879 | 3,056,496 | 3.1 M to 3.1 M (-0.26 %) |
Jan 09 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 11.09 | 29,039 | 322,043 | 3,064,485 | 3.1 M to 3.1 M (-0.94 %) |
Jan 09 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 11.16 | 50,000 | 558,000 | 3,093,524 | 3.1 M to 3.1 M (-1.59 %) |
Jan 07 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 11.05 | 50,000 | 552,500 | 3,143,524 | 3.2 M to 3.1 M (-1.57 %) |
Jan 07 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 11.01 | 66,290 | 729,853 | 3,193,524 | 3.3 M to 3.2 M (-2.03 %) |
Jan 05 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 11.02 | 34,621 | 381,523 | 3,259,814 | 3.3 M to 3.3 M (-1.05 %) |
Jan 05 2009 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 11.00 | 74,409 | 818,499 | 3,294,435 | 3.4 M to 3.3 M (-2.21 %) |
Dec 31 2008 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 11.00 | 67 | 737 | 3,368,844 | 3.4 M to 3.4 M (0.00 %) |
Dec 29 2008 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 11.00 | 1,255 | 13,805 | 3,368,911 | 3.4 M to 3.4 M (-0.04 %) |
Dec 29 2008 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 11.00 | 9,503 | 104,533 | 3,370,166 | 3.4 M to 3.4 M (-0.28 %) |
Dec 29 2008 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 11.00 | 38,735 | 426,085 | 3,379,669 | 3.4 M to 3.4 M (-1.13 %) |
Nov 25 2008 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Buy | P | 9.45 | 2,500 | 23,625 | 25,000 | 22.5 K to 25 K (+11.11 %) |
Nov 25 2008 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Buy | P | 9.41 | 4,281 | 40,284 | 22,500 | 18.2 K to 22.5 K (+23.50 %) |
Nov 25 2008 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Buy | P | 9.29 | 3,219 | 29,905 | 18,219 | 15 K to 18.2 K (+21.46 %) |
Nov 24 2008 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Option Exercise | A | 11.09 | 188,471 | 2,090,143 | 188,471 | |
Nov 20 2008 | NOVN | NOVEN PHARMACEUTIC ... | Lippman Joel | VP and Chief Medica ... | Option Exercise | A | 11.09 | 33,461 | 371,082 | 33,461 | |
Nov 20 2008 | NOVN | NOVEN PHARMACEUTIC ... | Venditti Anthony | VP - Marketing and ... | Option Exercise | A | 11.09 | 39,038 | 432,931 | 39,038 | |
Nov 20 2008 | NOVN | NOVEN PHARMACEUTIC ... | DINH STEVEN M | VP & Chief Scientif ... | Option Exercise | A | 11.09 | 39,038 | 432,931 | 39,038 | |
Nov 20 2008 | NOVN | NOVEN PHARMACEUTIC ... | Gilbert Richard P. | Vice President - Op ... | Option Exercise | A | 11.09 | 66,922 | 742,165 | 66,922 | |
Nov 20 2008 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Option Exercise | A | 11.09 | 66,922 | 742,165 | 66,922 | |
Nov 20 2008 | NOVN | NOVEN PHARMACEUTIC ... | EISENBERG JEFFREY F | Executive Vice Pres ... | Option Exercise | A | 11.09 | 71,702 | 795,175 | 71,702 | |
Oct 31 2008 | NOVN | NOVEN PHARMACEUTIC ... | OSS CAPITAL MANAGEMENT | 10% Owner | Sell | S | 10.65 | 6,286 | 66,946 | 3,418,404 | 3.4 M to 3.4 M (-0.18 %) |
Jul 15 2008 | NOVN | NOVEN PHARMACEUTIC ... | Lippman Joel | VP and Chief Medica ... | Option Exercise | A | 10.86 | 78,520 | 852,727 | 78,520 | |
Sep 02 2008 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Buy | P | 12.39 | 19,059 | 236,141 | 295,000 | 275.9 K to 295 K (+6.91 %) |
Sep 02 2008 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Buy | P | 12.38 | 527 | 6,524 | 275,941 | 275.4 K to 275.9 K (+0.19 %) |
Sep 02 2008 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Buy | P | 12.37 | 115 | 1,423 | 275,414 | 275.3 K to 275.4 K (+0.04 %) |
Sep 02 2008 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Buy | P | 12.36 | 299 | 3,696 | 275,299 | 275 K to 275.3 K (+0.11 %) |
Jul 02 2008 | NOVN | NOVEN PHARMACEUTIC ... | Venditti Anthony | VP - Marketing and ... | Option Exercise | A | 10.69 | 79,139 | 845,996 | 79,139 | |
Jun 16 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Buy | P | 11.36 | 200 | 2,272 | 44,119 | 43.9 K to 44.1 K (+0.46 %) |
Jun 16 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Buy | P | 11.35 | 100 | 1,135 | 43,919 | 43.8 K to 43.9 K (+0.23 %) |
Jun 16 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Buy | P | 11.34 | 126 | 1,429 | 43,819 | 43.7 K to 43.8 K (+0.29 %) |
Jun 16 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Buy | P | 11.33 | 351 | 3,977 | 43,693 | 43.3 K to 43.7 K (+0.81 %) |
Jun 16 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Buy | P | 11.32 | 400 | 4,528 | 43,342 | 42.9 K to 43.3 K (+0.93 %) |
Jun 16 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Buy | P | 11.31 | 1,174 | 13,278 | 42,942 | 41.8 K to 42.9 K (+2.81 %) |
Jun 16 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Buy | P | 11.30 | 2,908 | 32,860 | 41,768 | 38.9 K to 41.8 K (+7.48 %) |
Jun 16 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Buy | P | 11.29 | 1,449 | 16,359 | 38,860 | 37.4 K to 38.9 K (+3.87 %) |
Jun 16 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Buy | P | 11.28 | 7,818 | 88,187 | 37,411 | 29.6 K to 37.4 K (+26.42 %) |
Jun 16 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Buy | P | 11.27 | 5,696 | 64,194 | 29,593 | 23.9 K to 29.6 K (+23.84 %) |
Jun 16 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Buy | P | 11.26 | 2,352 | 26,484 | 23,897 | 21.5 K to 23.9 K (+10.92 %) |
Jun 16 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Buy | P | 11.25 | 2,426 | 27,293 | 21,545 | 19.1 K to 21.5 K (+12.69 %) |
Jun 09 2008 | NOVN | NOVEN PHARMACEUTIC ... | Savage Robert G. | Director | Grant | A | 0.00 | 10,121 | 0 | 20,619 | 10.5 K to 20.6 K (+96.41 %) |
Jun 09 2008 | NOVN | NOVEN PHARMACEUTIC ... | Yetter Wayne P. | Director | Grant | A | 0.00 | 10,121 | 0 | 31,313 | 21.2 K to 31.3 K (+47.76 %) |
Jun 09 2008 | NOVN | NOVEN PHARMACEUTIC ... | SATOW PHILLIP M | Director | Grant | A | 0.00 | 10,121 | 0 | 19,119 | 9 K to 19.1 K (+112.48 %) |
Jun 09 2008 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Grant | A | 0.00 | 10,121 | 0 | 29,777 | 19.7 K to 29.8 K (+51.49 %) |
Jun 09 2008 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Grant | A | 0.00 | 10,121 | 0 | 30,619 | 20.5 K to 30.6 K (+49.38 %) |
Jun 06 2008 | NOVN | NOVEN PHARMACEUTIC ... | DINH STEVEN M | VP & Chief Scientif ... | Option Exercise | A | 11.84 | 53,107 | 628,787 | 53,107 | |
Jun 09 2008 | NOVN | NOVEN PHARMACEUTIC ... | CLARKSON JOHN G | Director | Grant | A | 0.00 | 10,121 | 0 | 20,547 | 10.4 K to 20.5 K (+97.07 %) |
Jun 09 2008 | NOVN | NOVEN PHARMACEUTIC ... | BRAGINSKY SIDNEY | Director | Grant | A | 0.00 | 10,121 | 0 | 27,313 | 17.2 K to 27.3 K (+58.87 %) |
Jun 05 2008 | NOVN | NOVEN PHARMACEUTIC ... | Yetter Wayne P. | Director | Buy | P | 11.78 | 10,000 | 117,800 | 21,192 | 11.2 K to 21.2 K (+89.35 %) |
May 15 2008 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Buy | P | 9.82 | 10,000 | 98,200 | 275,000 | 265 K to 275 K (+3.77 %) |
May 15 2008 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Buy | P | 9.76 | 10,000 | 97,600 | 265,000 | 255 K to 265 K (+3.92 %) |
May 15 2008 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Buy | P | 9.86 | 2,884 | 28,436 | 255,000 | 252.1 K to 255 K (+1.14 %) |
May 15 2008 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Buy | P | 9.79 | 916 | 8,968 | 252,116 | 251.2 K to 252.1 K (+0.36 %) |
May 15 2008 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Buy | P | 9.73 | 1,000 | 9,730 | 251,200 | 250.2 K to 251.2 K (+0.40 %) |
May 15 2008 | NOVN | NOVEN PHARMACEUTIC ... | Brandt Peter C. | President and CEO | Buy | P | 9.69 | 200 | 1,938 | 250,200 | 250 K to 250.2 K (+0.08 %) |
Jun 03 2008 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Buy | P | 11.42 | 1,030 | 11,763 | 19,656 | 18.6 K to 19.7 K (+5.53 %) |
Jun 03 2008 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Buy | P | 11.41 | 500 | 5,705 | 18,626 | 18.1 K to 18.6 K (+2.76 %) |
Jun 03 2008 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Buy | P | 11.40 | 2,870 | 32,718 | 18,126 | 15.3 K to 18.1 K (+18.81 %) |
May 19 2008 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Buy | P | 10.90 | 8,100 | 88,290 | 20,498 | 12.4 K to 20.5 K (+65.33 %) |
May 19 2008 | NOVN | NOVEN PHARMACEUTIC ... | DENKHAUS DONALD A | Director | Buy | P | 10.89 | 1,900 | 20,691 | 12,398 | 10.5 K to 12.4 K (+18.10 %) |
May 15 2008 | NOVN | NOVEN PHARMACEUTIC ... | GRANADILLO PEDRO P | Director | Buy | P | 9.89 | 5,000 | 49,450 | 15,256 | 10.3 K to 15.3 K (+48.75 %) |
May 14 2008 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Buy | P | 9.78 | 44 | 430 | 15,000 | 15 K to 15 K (+0.29 %) |
May 14 2008 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Buy | P | 9.79 | 1,956 | 19,149 | 14,956 | 13 K to 15 K (+15.05 %) |
May 14 2008 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Buy | P | 9.80 | 4,500 | 44,100 | 13,000 | 8.5 K to 13 K (+52.94 %) |
May 14 2008 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Buy | P | 9.81 | 3,100 | 30,411 | 8,500 | 5.4 K to 8.5 K (+57.41 %) |
May 14 2008 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Buy | P | 9.84 | 100 | 984 | 5,400 | 5.3 K to 5.4 K (+1.89 %) |
May 14 2008 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Buy | P | 9.86 | 100 | 986 | 5,300 | 5.2 K to 5.3 K (+1.92 %) |
May 14 2008 | NOVN | NOVEN PHARMACEUTIC ... | PRICE MICHAEL DENNIS | VP and Chief Financ ... | Buy | P | 9.87 | 1,000 | 9,870 | 5,200 | 4.2 K to 5.2 K (+23.81 %) |